IMVT
HEALTHCAREImmunovant Inc
$28.67+0.83 (+2.98%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving IMVT Today?
No stock-specific AI insight has been generated for IMVT yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$13.52$30.09
$28.67
Fundamentals
Market Cap$5.8B
P/E Ratio—
EPS$-2.67
Dividend Yield—
Dividend / Share—
ROE-0.7%
Profit Margin—
Debt / Equity—
Trading
Volume1.3M
Avg Volume (10D)—
Shares Outstanding203.5M
IMVT News
21 articles- Generalized Myasthenia Gravis Market on the Brink of Change: 8 Promising Late-Stage Drugs Signal a New Treatment Era | DelveInsightGlobeNewswire Inc.·Apr 15, 2026
- IMVT Stock Falls 2.4% as Batoclimab Misses Late-Stage Study EndpointsYahoo Finance·Apr 6, 2026
- Should Brepocitinib’s New Trials and Batoclimab’s Setback Require Action From Roivant Sciences (ROIV) Investors?Yahoo Finance·Apr 3, 2026
- Sector Update: Health Care Stocks Softer Late AfternoonYahoo Finance·Apr 2, 2026
- Sector Update: Health Care Stocks Softer Thursday AfternoonYahoo Finance·Apr 2, 2026
- Immunovant Batoclimab Flops in Phase 3 TED as Roivant Expands Brepocitinib Into LPPMarketbeat·Apr 2, 2026
- Immunovant eye drug flunks Phase 3 studies; Beam sickle cell data published in NEJMBiopharmadive·Apr 2, 2026
- Immunovant shares plunge after phase 3 trials fails to meet primary endpointYahoo Finance·Apr 2, 2026
- Immunovant Announces Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED)GlobeNewswire Inc.·Apr 2, 2026
- Roivant Announces Expansion of Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP) and Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED)Yahoo Finance·Apr 2, 2026
- A Healthcare Hedge Fund Just Added $24.5 Million in Immunovant Stock. Should you?Motley Fool·Mar 15, 2026
- Assessing Immunovant (IMVT) Valuation After Recent Share Price WeaknessYahoo Finance·Mar 14, 2026
- Immunovant Stock Up 30% as Investor Trims Stake by $3 Million, But Here's Why It Still Seems BullishMotley Fool·Mar 11, 2026
- Truth Social Stock Down 50% as One Investor Sells Off Nearly 800,000 SharesMotley Fool·Mar 11, 2026
- Immunovant Stock Surges 17% in 3 Months: What's Driving It?Yahoo Finance·Mar 5, 2026
- Immunovant, Inc. (IMVT) Analysts Raise Price Targets Following Q3 Earnings UpdateYahoo Finance·Mar 4, 2026
- Assessing Immunovant (IMVT) Valuation As Shares Deliver A 25% One Year ReturnYahoo Finance·Feb 23, 2026
- Indivior Pharmaceuticals to Report Q4 Earnings: What's in the Cards?Yahoo Finance·Feb 19, 2026
- Arcutis Biotherapeutics to Report Q4 Earnings: What's in the Cards?Yahoo Finance·Feb 17, 2026
- Recursion Pharmaceuticals to Report Q4 Earnings: What's in the Cards?Yahoo Finance·Feb 17, 2026
- IMVT Posts Narrower-Than-Expected Q3 Loss, Pipeline in FocusYahoo Finance·Feb 9, 2026
All 21 articles loaded
Price Data
Open$28.27
Previous Close$27.84
Day High$28.59
Day Low$27.14
52 Week High$30.09
52 Week Low$13.52
52-Week Range
$13.52$30.09
$28.67
Fundamentals
Market Cap$5.8B
P/E Ratio—
EPS$-2.67
Dividend Yield—
Dividend / Share—
ROE-0.7%
Profit Margin—
Debt / Equity—
Trading
Volume1.3M
Avg Volume (10D)—
Shares Outstanding203.5M
About Immunovant Inc
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. The company is headquartered in New York, New York.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—